Your Location:Home >Products >API >24305-27-9
Appearance:COA
Purity:99%
Properties |
White or yellowish-white powder, hygroscopic. Mr 362. Soluble in water, methanol, and ethanol; partially insoluble in chloroform; completely insoluble in ether and pyridine. Stable in solution at <15°C for more than a year; partially (1%) degraded at 40°C for 6 months. Resistant to proteolytic enzymes. Inactivated by diazotized sulfanilic acid (Pauly reagent). Plasma half-life is 2–6min. |
Synthesis and release |
TRH secretion is regulated by norepinephrine, histamine, dopamine, and serotonin. Cold-induced secretion of TSH from the rat anterior pituitary involves α-adrenergic regulation of TRH secretion. TRH neurons in the PVN are negatively regulated by thyroid hormones through a feedback mechanism. Locally produced T3 is taken by these neurons to regulate transcription, posttranslational modification, and degradation of TRH. |
Gene, mRNA, and precursor |
TRH is synthesized from a precursor that contains multiple copies of the TRH progenitor sequence GlnHis-Pro-Gly, which is flanked by dibasic cleavage sites at its N- and C-termini. The number of progenitor sequences in a precursor is diversified: six in humans, five in rats, four in chicken, seven in frogs, and six to eight in fish. Human preproTRH gene, TRH, location 3q13.3–q21, consists of three exons. |
Clinical implications |
The majority of thyroid disfunction is due to primary thyroid disease. On the other hand, central thyroid disfunction is related to a disorder of the pituitary (TSH), hypothalamus (TRH), or hypothalamic-pituitary portal circulation. Isolated central hypothyroidism was reported in a patient with inactivating mutations in the TRH-R gene. |
Receptors |
TRH-R is a seven-transmembrane-domain GPCR. Two major types of TRH-Rs (type I receptor including TRH-R1 and TRH-R3, and type II receptor [TRH-R2]), have been identified in vertebrates . Three and four subtypes of TRH-Rs have been identified in Xenopus laevis and teleost species, respectively.?TRH action is mediated via a membrane receptor mainly coupled to Gq/11 protein. TRH induces the mobilization of intracellular Ca2+ and the activation of PKC in target cells. |
Description |
Thyrotropin releasing hormone (TRH) is a tripeptide hypothalamic regulatory hormone, encoded by the gene mapped to human chromosome 3q13.3-q21. TRH is expressed in a variety of organs including central nervous system (CNS) and gastrointestinal tract. The first hypothalamic hypophysiotropic neurohormone identified, TRH consists of the tripeptide pGlu-His-ProNH2. It stimulates the secretion ofthyroid-stimulating hormone (TSH), prolactin (PRL), and growth hormone (GH), and also functions as a neurotransmitter and neuromodulator. TRH was first isolated and characterized in 1969 by Roger Guillemin and Andrew Schally, who shared the Nobel Prize in Physiology or Medicine in 1977 “for their discoveries concerning the peptide hormone production of the brain.”The biosynthesis of TRH from a precursor molecule was first clarified in 1984 by isolation of a preproTRH cDNA from the skin of Xenopus laevis.? The structure of the TRH receptor (TRH-R) was first deduced from a cDNA isolated from the mouse pituitary in 1990. |
Uses |
Thyrotropin-Releasing Hormone is a hypothalamic hypophysiotropic neuropeptide, which has the ability to stimulate the release of thyroid-stimulating hormone in mammals. It is proven that Thyrotropin-Releasing Hormone can be used to accelerate wound healing. TRH (200–500μg) administered intravenously to normal subjects causes a rise in TSH levels within 15–30min, resulting in an increase in T3 levels within 90–150min. In primary hypothyroidism, TSH hyperresponse to TRH occurs, with a typical elevation in the basal TSH levels. In secondary (pituitary) hypothyroidism, an impaired TSH response to TRH occurs, whereas in tertiary (hypothalamic) hypothyroidism normal or increased TSH response to TRH occurs. Protirelin is used to test the response of the anterior pituitary to TRH in people who may have medical conditions of thyroid function, including hyperthyroidism, Graves’ disease, and hypothyroidism. In addition, TRH has been used to assess the ability of the prolactin secretion in the pituitary. |
Indications |
Thyrotropin-releasing hormone, or protirelin, consists of three amino acids. TRH (Relefact TRH) is used for tests to distinguish primary from secondary hypothyroidism. |
Biochem/physiol Actions |
Thyrotropin releasing hormone (TRH) stimulates production and secretion of thyrotropin (TSH) and prolactin from the anterior pituitary. It also plays a vital role as a neurotransmitter and neuromodulator. |
InChI:InChI=1/C16H22N6O4/c17-14(24)12-2-1-5-22(12)16(26)11(6-9-7-18-8-19-9)21-15(25)10-3-4-13(23)20-10/h7-8,10-12H,1-6H2,(H2,17,24)(H,18,19)(H,20,23)(H,21,25)
Three new fluorous supports for peptide ...
Thyrotropin-Releasing Hormone (TRH), a t...
Peptides containing the cyclic product o...
N(α)-tert-Butyloxycarbonyl-N(π)-2-adaman...
-
-
-
Nπ-2-Adamantyloxymethylhistidine, His(Nπ...
L-Pyroglutamic acid
H-His-Pro-NH2*2HCl
Pyr-His-Pro-NH2
Conditions | Yield |
---|---|
With HONB; N-ethyl-N,N-diisopropylamine; diisopropyl-carbodiimide; In N,N-dimethyl-formamide; at 20 ℃; for 36h;
|
Gln-His-Pro-NH2
Pyr-His-Pro-NH2
Conditions | Yield |
---|---|
With acetic acid; In 1,4-dioxane; at 40 ℃; for 12h;
|
81% |
Gln-His-Pro-NH2
pyroglutamic acid 2,4,6-trichlorophenylester
Adpoc-His(Adpoc)-Pro-NH2
Pyroglutamylhistidine
C17H21F3N6O4
C17H21F3N6O4
CAS:119356-77-3
CAS:868844-74-0
CAS:22374-89-6
CAS:859-18-7